EXPLORE THE SCIENCE
TL;DR: A 2026 paper in Neuropsychopharmacology argued that cannabidiol (CBD), a non-intoxicating cannabis compound, has plausible psychiatric and neurological uses, but clinical claims need standardized products, exposure tracking, and safety monitoring before…
Read article
TL;DR: A 2026 Phase I study in CNS Drugs found that a 400 mg powdered cannabidiol (CBD) formulation reached peak blood levels faster than oil-based Epidyolex, especially after a high-fat meal, while both products were generally well tolerated in healthy adults…
Read article
Researchers have made strides towards enabling personalized dosing for the commonly prescribed antidepressant escitalopram. Using robust clinical trial data, they developed an innovative population pharmacokinetics model that elucidates the impact of patient g…
Read article